Press Releases Xspray Pharma AB

Equities

XSPRAY

SE0009973563

Market Closed - Nasdaq Stockholm Other stock markets 11:29:59 2024-06-03 am EDT			5-day change	1st Jan Change
74.4 ^SEK	+0.27%		+16.07%	+86.00%

May. 23	Xspray Pharma AB Announces to Present Data At ASCO Highlighting Frequent Decideication of PPIs with TKIs in CML-Patients and Greater Than Expected Positive Effects on the Bioavailability of Crystalline Dasatinib	CI
May. 20	Xspray Pharma AB Appoints Linda Glimberg as Chief Operating Officer, Effective June 1, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

New number of shares and votes in Xspray Pharma after TO6	May. 31	AQ
Xspray to present data at ASCO highlighting frequent comedication of PPIs with TKIs in CML-patients and greater than expected negative effects on the bioavailability of crystalline dasatinib	May. 23	BU
Bulletin from the annual general meeting of Xspray Pharma AB (publ), 21 May 2024	May. 21	AQ
Xspray Pharma appoints Chief Operating Officer and changes the Management Team	May. 20	AQ
Xspray Pharma Q1 2024 - Reveal of XS025 and PDUFA is nearing	May. 13	AQ
Interim Report First Quarter 2024	May. 08	AQ
Xspray Pharma raises SEK 100.3 million through warrants TO6	May. 03	AQ
Xspray Pharma Announces Fourth Product Candidate, targeting USD 2.3 billion Market	Apr. 22	AQ
Xspray Pharma receives declaration of intent from Östersjöstiftelsen regarding exercise of TO6 warrants	Apr. 19	AQ
Important information to holders of warrants series TO6: subscription period begins today	Apr. 18	AQ
Notice of annual general meeting of Xspray Pharma AB (publ)	Apr. 18	AQ
Xspray Pharma receives declarations of intent from its largest owners regarding exercise of TO6 warrants	Apr. 10	AQ
Xspray Pharma publishes its Annual Report 2023	Mar. 27	AQ
Xspray Pharma Q4 2023 - NDA-resubmission accepted by the FDA	Feb. 16	AQ
Interim Report Fourth Quarter 2023	Feb. 14	AQ
FDA Accepts Xspray Pharma's NDA-resubmission for Dasynoc, PDUFA Date set to 31 July	Feb. 13	AQ
FDA Accepts Xspray Pharma’s NDA-resubmission for Dasynoc® – PDUFA Date set to 31 July 2024	Feb. 12	BU
FDA Accepts Xpray Pharma’s NDA-resubmission for Dasynoc® – PDUFA Date set to 31 July	Feb. 12	AQ
Xspray Pharma appoints Michael af Winklerfelt as acting CFO	Feb. 07	AQ
New number of shares and votes in Xspray Pharma	Dec. 29	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Xspray Pharma AB

Equities

XSPRAY

SE0009973563

Press Releases

Filters